Literature DB >> 2117167

Criteria for alpha 1-antitrypsin substitution.

K Viskum1, A Kok-Jensen.   

Abstract

The pharmacology and safety of substitution treatment intravenously with alpha 1-antitrypsin (AAT) in patients deficient of AAT has been thoroughly investigated. The clinical efficacy of the treatment has so far not been established. The difficulties and uncertainties involved in defining the right persons for treatment, and determining the right time for a possible start of treatment are discussed. A controlled trail with participation of several European countries is suggested.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2117167     DOI： 10.1007/bf02718181

Source DB:  PubMed          Journal:  Lung        ISSN： 0341-2040            Impact factor:   2.584


  9 in total

1.  Decline in pulmonary function in patients with alpha 1-antitrypsin deficiency.

Authors:  T Evald; A Dirksen; S Keittelmann; K Viskum; A Kok-Jensen
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, PiZZ.

Authors:  M C Wu; S Eriksson
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

3.  Psychosocial effects of screening for somatic risk: the Swedish alpha 1 antitrypsin experience.

Authors:  T F McNeil; T Sveger; T Thelin
Journal:  Thorax       Date:  1988-07       Impact factor: 9.139

4.  Distribution of alpha-1-antitrypsin phenotypes in Sweden.

Authors:  K Hjalmarsson
Journal:  Hum Hered       Date:  1988       Impact factor: 0.444

Review 5.  Animal models of emphysema.

Authors:  G L Snider; E C Lucey; P J Stone
Journal:  Am Rev Respir Dis       Date:  1986-01

6.  Alpha 1-antitrypsin phenotypes and obstructive lung disease in the city of Oslo.

Authors:  A Gulsvik; M K Fagerhol
Journal:  Scand J Respir Dis       Date:  1979-10

7.  Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency.

Authors:  R C Hubbard; S Sellers; D Czerski; L Stephens; R G Crystal
Journal:  JAMA       Date:  1988-09-02       Impact factor: 56.272

8.  Alpha 1 antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. A survey by the British Thoracic Association.

Authors:  D C Hutchison; M J Tobin; P J Cook
Journal:  Br J Dis Chest       Date:  1983-01

Review 9.  Natural history of alpha-1-protease inhibitor deficiency.

Authors:  D C Hutchison
Journal:  Am J Med       Date:  1988-06-24       Impact factor: 4.965
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.